Quarterly ResultJul 9, 2026, 04:18 PM
Nurix Therapeutics Q2 Net Loss $(89.5)M; Revenue $9.0M
AI Summary
Nurix Therapeutics reported a net loss of $(89.5) million for the three months ended May 31, 2026, significantly wider than the $(43.5) million loss in the prior year. Total revenue decreased to $9.0 million from $44.1 million, primarily due to the absence of license revenue. The company continues to incur substantial losses, with an accumulated deficit of $(1.2) billion, and anticipates needing significant additional funding to support its operations and clinical development.
Key Highlights
- Q2 2026 net loss widened to $(89.5) million from $(43.5) million year-over-year.
- Q2 2026 total revenue decreased to $9.0 million from $44.1 million year-over-year.
- Research and development expenses increased to $87.7 million in Q2 2026.
- Cash, cash equivalents, and marketable securities totaled $443.5 million as of May 31, 2026.
- Accumulated deficit reached $(1.2) billion as of May 31, 2026.
- Net cash used in operating activities was $(168.5) million for the six months.
- $300.0 million remains available under the "at the market" equity distribution agreement.
- Company expects to incur losses for several years and needs substantial additional funding.
Price Impact
More from NRIX